Guardant Health closes enrolment in COBRA study following interim analysis
The company is conducting several ongoing studies with the aim of demonstrating the effectiveness of its current MRD…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Sep 23
The company is conducting several ongoing studies with the aim of demonstrating the effectiveness of its current MRD…
31 Aug 23
Integrated into LivaNova’s Essenz Perfusion System, Essenz ILMB is designed to provide perfusionists with accurate and continuous measurement…
31 Aug 23
The partnership will combine DoMore’s CE-IVDD marked Histotype Px Colorectal digital biomarker with Proscia’s CE-IVDR marked Concentriq Dx…
31 Aug 23
As a ComboMATCH-designated lab, Exact Sciences will use its OncoExTra test to examine tumour tissue and associated normal…
30 Aug 23
The partnership aims to manufacture medical diagnostic devices that rapidly detect and differentiate multiple infections, and uses printed…
28 Aug 23
SURF intends to help sponsors make an initial feasibility assessment for using real-world data to provide substantial evidence…
25 Aug 23
The fully automated mass spectrometry system is designed for diagnosis, evaluation, and monitoring of patients with monoclonal gammopathies
25 Aug 23
The new Tokyo-based JV company will use BostonGene’s high-complexity molecular technology and advanced biocomputational algorithms to expedite the…
23 Aug 23
The clinical study, conducted by researchers from major academic centres and urology practices across the US, evaluated the…
23 Aug 23
GeneseeqPrime and GeneseeqPrime HRD are indicated for solid tumour genomic profiling while Hemasalus DNA/Hemarna RNA is approved for…